Dawn Odom
YOU?
Author Swipe
View article: mRNA and Protein Subunit COVID-19 Vaccine Reactogenicity and the Relationship to Productivity for Healthcare Workers and First Responders
mRNA and Protein Subunit COVID-19 Vaccine Reactogenicity and the Relationship to Productivity for Healthcare Workers and First Responders Open
Objectives To compare the percentage of participants that experienced any solicited systemic reactogenicity symptom after one dose of the updated 2024–2025 adjuvanted protein-based Novavax (NVX; JN.1) or Pfizer–BioNTech mRNA (PFZ; KP.2) CO…
View article: Reactogenicity Differences between Adjuvanted, Protein-Based and Messenger Ribonucleic Acid (mRNA)-Based COVID-19 Vaccines
Reactogenicity Differences between Adjuvanted, Protein-Based and Messenger Ribonucleic Acid (mRNA)-Based COVID-19 Vaccines Open
Participants in studies investigating COVID-19 vaccines commonly report reactogenicity events, and concerns about side effects may lead to a reluctance to receive updated COVID-19 vaccinations. A real-world, post hoc analysis, observationa…
View article: Reactogenicity Differences between COVID-19 Vaccines: A Pro-spective Observational Study in the United States and Canada
Reactogenicity Differences between COVID-19 Vaccines: A Pro-spective Observational Study in the United States and Canada Open
Participants in studies investigating COVID-19 vaccines commonly report reactogenicity events, and concerns about side effects may lead to reluctance to receive updated COVID-19 vaccinations. A real-world, post hoc analysis, observational …
View article: Burden and Impact of Reactogenicity among Adults Receiving COVID-19 Vaccines in the United States and Canada: Results from a Prospective Observational Study
Burden and Impact of Reactogenicity among Adults Receiving COVID-19 Vaccines in the United States and Canada: Results from a Prospective Observational Study Open
As SARS-CoV-2 variants continue to emerge, vaccination remains a critical tool to reduce the COVID-19 burden. Vaccine reactogenicity and the impact on work productivity/daily activities are recognized as contributing factors to vaccine hes…
View article: Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: An analysis of the phase III ARAMIS trial
Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: An analysis of the phase III ARAMIS trial Open
In patients with nmCRPC who are generally asymptomatic, darolutamide maintained HRQoL by significantly delaying time to deterioration of prostate cancer-specific quality of life and disease-related symptoms versus placebo.
View article: Effect of Regorafenib in Delaying Definitive Deterioration in Health-Related Quality of Life in Patients with Advanced Cancer of Three Different Tumor Types
Effect of Regorafenib in Delaying Definitive Deterioration in Health-Related Quality of Life in Patients with Advanced Cancer of Three Different Tumor Types Open
A pooled analysis of four phase 3 trials demonstrated that regorafenib delayed a clinically relevant exploratory endpoint, defined as TUDD, compared with placebo across three different tumor types (mCRC, GIST, and HCC), which supports a no…
View article: A prospective observational study of patient-reported functioning and quality of life in advanced and metastatic breast cancer utilizing a novel mobile application
A prospective observational study of patient-reported functioning and quality of life in advanced and metastatic breast cancer utilizing a novel mobile application Open
View article: Quality of life is maintained with ixazomib maintenance in post‐transplant newly diagnosed multiple myeloma: The TOURMALINE‐MM3 trial
Quality of life is maintained with ixazomib maintenance in post‐transplant newly diagnosed multiple myeloma: The TOURMALINE‐MM3 trial Open
Objectives Health‐related quality of life (HRQoL) is particularly important during maintenance therapy (MT) in newly diagnosed multiple myeloma post‐transplant, when disease symptoms are limited. Methods We assessed HRQoL in patients rando…
View article: PSS21 EFFECT OF ISTENT INJECT TRABECULAR MICRO-BYPASS ON PATIENT-REPORTED OUTCOMES FOR THOSE WITH OPEN-ANGLE GLAUCOMA AND COEXISTING CATARACTS
PSS21 EFFECT OF ISTENT INJECT TRABECULAR MICRO-BYPASS ON PATIENT-REPORTED OUTCOMES FOR THOSE WITH OPEN-ANGLE GLAUCOMA AND COEXISTING CATARACTS Open
View article: Effect of regorafenib in delaying definitive deterioration in health-related quality of life across three tumor types
Effect of regorafenib in delaying definitive deterioration in health-related quality of life across three tumor types Open
View article: Health-related quality of life (HRQOL) outcomes of oral ixazomib maintenance therapy post autologous stem cell transplant (ASCT) in newly diagnosed multiple myeloma (NDMM) from tourmaline-MM3
Health-related quality of life (HRQOL) outcomes of oral ixazomib maintenance therapy post autologous stem cell transplant (ASCT) in newly diagnosed multiple myeloma (NDMM) from tourmaline-MM3 Open
View article: PF626 HEALTH‐RELATED QUALITY OF LIFE (HRQOL) OUTCOMES OF ORAL IXAZOMIB MAINTENANCE THERAPY POST AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) FROM TOURMALINE‐MM3
PF626 HEALTH‐RELATED QUALITY OF LIFE (HRQOL) OUTCOMES OF ORAL IXAZOMIB MAINTENANCE THERAPY POST AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) FROM TOURMALINE‐MM3 Open
Background: Maintenance therapy (MT) in NDMM has been increasingly used to prolong duration of response achieved by ASCT. TOURMALINE‐MM3 is a phase 3, double‐blind, placebo‐controlled study, where ixazomib improved PFS, and is the first st…
View article: A prospective observational study of mobile application-based patient-reported outcomes (PRO) in advanced breast cancer: Interim baseline data from the MADELINE study
A prospective observational study of mobile application-based patient-reported outcomes (PRO) in advanced breast cancer: Interim baseline data from the MADELINE study Open
Background: MADELINE is a multicenter study enrolling women with advanced/metastatic breast cancer (ABC/MBC) receiving palbociclib in combination with an aromatase inhibitor (AI) as initial endocrine therapy or fulvestrant after progressio…
View article: An analysis of factors associated with influenza, pneumoccocal, Tdap, and herpes zoster vaccine uptake in the US adult population and corresponding inter-state variability
An analysis of factors associated with influenza, pneumoccocal, Tdap, and herpes zoster vaccine uptake in the US adult population and corresponding inter-state variability Open
Despite longstanding recommendations for routine vaccination against influenza; pneumococcal; tetanus, diphtheria, acellular pertussis (Tdap); and herpes zoster (HZ) among the United States general adult population, vaccine uptake remains …
View article: Utilization and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine from an observational study in Europe
Utilization and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine from an observational study in Europe Open
Objective To examine treatment utilization patterns and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine in routine clinical practice. Background Clinical trials support onabotulinumtoxinA for the prophylaxis…
View article: Comparison of palbociclib in combination with letrozole or fulvestrant with endocrine therapies for advanced/metastatic breast cancer: network meta-analysis
Comparison of palbociclib in combination with letrozole or fulvestrant with endocrine therapies for advanced/metastatic breast cancer: network meta-analysis Open
Background: Palbociclib is the first cyclin-dependent kinase 4/6 inhibitor approved in the United States for HR+/HER2- advanced/metastatic breast cancer, in combination with letrozole as initial endocrine-based therapy in postmenopa…
View article: A Matching-Adjusted Indirect Comparison of Sonidegib and Vismodegib in Advanced Basal Cell Carcinoma
A Matching-Adjusted Indirect Comparison of Sonidegib and Vismodegib in Advanced Basal Cell Carcinoma Open
Objectives . Based on single-arm trial data (BOLT), sonidegib was approved in the US and EU to treat locally advanced basal cell carcinomas (BCCs) ineligible for curative surgery or radiotherapy. Vismodegib, the other approved targeted the…
View article: Anaphylaxis in Schools: Results of the EPIPEN4SCHOOLS Survey Combined Analysis
Anaphylaxis in Schools: Results of the EPIPEN4SCHOOLS Survey Combined Analysis Open
A pilot survey described the characteristics of anaphylactic events occurring in an initial set of participating U.S. schools during the 2013-2014 school year. This survey was subsequently readministered to large school districts, which we…
View article: A Matching Adjusted Indirect Comparison Of Sonidegib And Vismodegib In Advanced Basal Cell Carcinoma
A Matching Adjusted Indirect Comparison Of Sonidegib And Vismodegib In Advanced Basal Cell Carcinoma Open
View article: EPIPEN4SCHOOLS® Survey Combined Analysis: Staff Training and Use of Epinephrine Auto-Injectors
EPIPEN4SCHOOLS® Survey Combined Analysis: Staff Training and Use of Epinephrine Auto-Injectors Open
View article: EPIPEN4SCHOOLS® Survey Combined Analysis: Prevalence and Triggers of Anaphylactic Events
EPIPEN4SCHOOLS® Survey Combined Analysis: Prevalence and Triggers of Anaphylactic Events Open
View article: Brentuximab Vedotin in Patients at Increased Risk of Hodgkin Lymphoma Progression Post Autologous Stem Cell Transplant: Evaluation of Healthcare Resource Utilization in the Aethera Trial
Brentuximab Vedotin in Patients at Increased Risk of Hodgkin Lymphoma Progression Post Autologous Stem Cell Transplant: Evaluation of Healthcare Resource Utilization in the Aethera Trial Open